Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer

Siegel, 2019, Cancer statistics, CA Cancer J Clin, 69, 7, 10.3322/caac.21551 Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, 379, 2395, 10.1056/NEJMoa1809775 Katz, 2014, Management of borderline resectable pancreatic cancer, Semin Radiat Oncol, 24, 105, 10.1016/j.semradonc.2013.11.006 Krishnan, 2007, Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy, Cancer, 110, 47, 10.1002/cncr.22735 Herman, 2015, Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma, Cancer, 121, 1128, 10.1002/cncr.29161 Kharofa, 2014, Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer, Radiother Oncol, 113, 41, 10.1016/j.radonc.2014.09.010 Ajani, 2006, Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response, J Clin Oncol, 24, 3953, 10.1200/JCO.2006.06.4840 Donohoe, 2013, Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard, Ann Surg, 258, 784, 10.1097/SLA.0b013e3182a66588 Fokas, 2014, Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial, J Clin Oncol, 32, 1554, 10.1200/JCO.2013.54.3769 Fokas, 2017, Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer, J Natl Cancer Inst, 109, 10.1093/jnci/djx095 Sauer, 2004, Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 351, 1731, 10.1056/NEJMoa040694 van Hagen, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 2074, 10.1056/NEJMoa1112088 Chuong, 2016, Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer, J Gastrointest Oncol, 7, 221 Dohopolski, 2017, Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer-patterns of care and overall survival, J Gastrointest Oncol, 8, 766, 10.21037/jgo.2017.08.04 Mellon, 2017, Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy, Acta Oncol, 56, 391, 10.1080/0284186X.2016.1256497 Wild, 2013, A phase 2 multi-institutional study to evaluate gemcitabine and fractionated stereotactic radiotherapy for unresectable, locally advanced pancreatic adenocarcinoma, Pract Radiat Oncol, 3, S4, 10.1016/j.prro.2013.01.016 Mellon, 2016, Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer, J Gastrointest Oncol, 7, 547, 10.21037/jgo.2016.03.15 Moningi, 2015, The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience, Ann Surg Oncol, 22, 2352, 10.1245/s10434-014-4274-5 Chuong, 2013, Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated, Int J Radiat Oncol Biol Phys, 86, 516, 10.1016/j.ijrobp.2013.02.022 Schellenberg, 2008, Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 72, 678, 10.1016/j.ijrobp.2008.01.051 Schellenberg, 2011, Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 81, 181, 10.1016/j.ijrobp.2010.05.006 Mahadevan, 2010, Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 78, 735, 10.1016/j.ijrobp.2009.08.046 Mahadevan, 2011, Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer, Int J Radiat Oncol Biol Phys, 81, e615, 10.1016/j.ijrobp.2011.04.045 Zhao, 2012, Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis, Ann Diagn Pathol, 16, 29, 10.1016/j.anndiagpath.2011.08.005 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Peron, 2016, An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma, Oncotarget, 7, 82953, 10.18632/oncotarget.12761 Gillen, 2010, Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, PLoS Med, 7, 10.1371/journal.pmed.1000267 Greenblatt, 2011, Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy, Ann Surg Oncol, 18, 2126, 10.1245/s10434-011-1594-6 Tsuruga, 2013, Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer, World J Gastroenterol, 19, 2569, 10.3748/wjg.v19.i16.2569 Vinogradskiy, 2019, The clinical and dosimetric impact of real-time target tracking in pancreatic SBRT, Int J Radiat Oncol Biol Phys, 103, 268, 10.1016/j.ijrobp.2018.08.021 Strasberg, 2009, The accordion severity grading system of surgical complications, Ann Surg, 250, 177, 10.1097/SLA.0b013e3181afde41 Katz, 2009, Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma, Ann Surg Oncol, 16, 836, 10.1245/s10434-008-0295-2 Winter, 2006, 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience, J Gastrointest Surg, 10, 1199, 10.1016/j.gassur.2006.08.018 Neoptolemos, 2001, Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial, Ann Surg, 234, 758, 10.1097/00000658-200112000-00007 Millikan, 1999, Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas, Am Surg, 65, 618, 10.1177/000313489906500704 Mellon, 2015, Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma, Acta Oncol, 54, 979, 10.3109/0284186X.2015.1004367 Kharofa, 2019, Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer, Am J Clin Oncol, 42, 247, 10.1097/COC.0000000000000518 Katz, 2016, Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101, JAMA Surg, 151, 10.1001/jamasurg.2016.1137 Ahmad, 2020, Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma, Ann Surg, 272, 481, 10.1097/SLA.0000000000004155 Palta, 2019, Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline, Pract Radiat Oncol, 9, 322, 10.1016/j.prro.2019.06.016 Crane, 2002, Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?, Int J Radiat Oncol Biol Phys, 52, 1293, 10.1016/S0360-3016(01)02740-7 Kim, 2002, Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?, J Gastrointest Surg, 6, 763, 10.1016/S1091-255X(02)00017-3 Hosein, 2012, A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma, BMC Cancer, 12, 199, 10.1186/1471-2407-12-199 Koong, 2004, Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 58, 1017, 10.1016/j.ijrobp.2003.11.004 Koong, 2005, Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys, 63, 320, 10.1016/j.ijrobp.2005.07.002 Rwigema, 2011, Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas, Am J Clin Oncol, 34, 63, 10.1097/COC.0b013e3181d270b4 Chatterjee, 2012, Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome, Cancer, 118, 3182, 10.1002/cncr.26651 Baine, 2019, Incidence and patterns of locoregional failure after stereotactic body radiation therapy for pancreatic adenocarcinoma, Pract Radiat Oncol, 9, e29, 10.1016/j.prro.2018.06.006 Zhu, 2019, Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design, Int J Radiat Oncol Biol Phys, 104, 101, 10.1016/j.ijrobp.2019.01.075